Navigation Links
Diversion of ambulances associated with increased risk of death for heart-attack patients
Date:6/12/2011

Among Medicare patients with heart attack in 4 California counties, diversion of ambulance traffic by the nearest emergency department for 12 hours or more was associated with an increased risk of death for up to one year, according to a study in the June 15 issue of JAMA. This study is being released early online to coincide with its presentation at the AcademyHealth Annual Research Meeting.

Recent reports have described the state of emergency departments (EDs) in the United States as reaching a breaking point, with the ED system experiencing increased utilization but decreased capacity. These trends have led to problems for patients, such as longer waiting times, overextended staff and disruptions to ambulance services, according to background information in the article. Ambulance diversion, a practice in which EDs are temporarily closed to ambulance traffic due to overcrowding or lack of available resources, might be especially problematic for patients experiencing time-sensitive conditions, such as acute myocardial infarction (AMI; heart attack). There is little empirical evidence to show whether diversion is associated with worse patient outcomes.

Yu-Chu Shen, Ph.D., of the Naval Postgraduate School, Monterey, Calif., and National Bureau of Economic Research, Cambridge, Mass., and Renee Y. Hsia, M.D., M.Sc., of the University of California, San Francisco conducted a study to examine whether temporary ED closure on the day a patient experiences AMI is associated with increased mortality. The study included 13,860 Medicare patients with AMI within 4 California counties (Los Angeles, San Francisco, San Mateo, and Santa Clara) whose admission date was between 2000 and 2005. Data included 100 percent Medicare claims data that covered admissions between 2000 and 2005, linked with date of death until 2006, and daily ambulance diversion logs from the same 4 counties. The researchers indentified 149 EDs as the nearest ED to these patients
'/>"/>

Contact: Alan Richmond
abrichmo@nps.edu
831-656-3649
JAMA and Archives Journals
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
2. Certain pain medications do not appear to be associated with skin cancer risk
3. News brief: ALDH associated with worse overall survival in patients with pancreatic adenocarcinoma
4. New research shows emotional impact of low sexual desire and associated distress
5. Increased HAART coverage associated with 50 percent drop
6. Pretreatment SUV associated with head and neck cancer treatment outcomes, may help decide treatment plans
7. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
8. MedQuist Launches EHR Integration for Dictations Associated with Template-based Clinical Documentation
9. Hormone thought to slow aging associated with increased risk of cancer death
10. Common osteoporosis drugs are associated with a decrease in risk of breast cancer
11. Coffee Drinking and Caffeine Associated With Reduced Risk of Hospitalization for Heart Rhythm Disturbances
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... New York (PRWEB) , ... ... ... trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence is now ... 28th, 2015 was well received with a 94% approval rating from the ...
(Date:7/31/2015)... VA (PRWEB) , ... July 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, and ... and regional mesothelioma experts. The conference is a collaborative effort between the Mesothelioma ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just Age” will ... thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at Foxwoods Resort ... 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other management and ...
(Date:7/31/2015)... ... ... The Mount Sinai Health System will work with Columbia Care LLC, a ... treatments. The collaboration moves into the next phase with the recent decision by the ... licenses to produce and dispense medical marijuana. , Mount Sinai and Columbia Care ...
(Date:7/31/2015)... ... 2015 , ... Like nearly every other form of surgery, it shouldn't come ... effective and less intrusive and painful. Leading these advances in the United States ... currently stands as the only doctor in the United States who is qualified to ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:New York Area Mesothelioma Specialists to Present at Conference 2Health News:New York Area Mesothelioma Specialists to Present at Conference 3Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3Health News:Loria Medical Penile Enlargement Center to Expand, Offering Practice Partnership to Doctors 2
... Better understanding of genetic, biological causes could lead more ... (HealthDay News) -- When people understand the genetics and ... blame those with the eating disorder for their illness, ... (UNC) study. , "This is a potentially important ...
... of women showed effect lasted long after program ended ... exercises can help relieve chronic neck pain, says a ... Care & Research . , Previous studies have produced ... pain, but there hasn,t been enough high-quality research to ...
... immune system should fight tumors, researchers say , , ... to fight ovarian and breast cancer are in ... their safety and effectiveness, researchers report. , The ... Coukos, an assistant professor at the University of ...
... The state,s most highly-respected minds in medicine and emergency ... to improve Missouri,s emergency response systems, JEFFERSON CITY, ... will meet Tuesday, January 15, 2008, to compile,recommendations for ... the mortality and morbidity associated with stroke and ST-Segment,Elevation ...
... With a continued focus on,quality and ... to focus on opportunities for streamlining processes ... functions for,manufacturing organizations, the majority of the ... centralization could provide several,worthwhile benefits, as found ...
... for Collective Bargaining, ,Prompt Pay,Legislation, WASHINGTON, Jan. ... of Inspector General (OIG) on independent pharmacy payments ... Hill and runs counter to,claims from the independent ... today., "This report will raise eyebrows among ...
Cached Medicine News:Health News:Science Could Erase Stigma of Anorexia 2Health News:Strength Training Eases Chronic Neck Pain 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 2Health News:Vaccines for Ovarian and Breast Cancer in Early Trials 3Health News:Time Critical Diagnosis Task Force Convenes in Jefferson City 2Health News:Manufacturing Organizations Identify Efficiencies in Maintenance Functions 2Health News:PCMA: New Study on Independent Pharmacy Reimbursements Will 'Raise Eyebrows' on Capitol Hill 2
(Date:7/30/2015)... July 30, 2015 PTC Therapeutics, Inc. (NASDAQ: ... reported financial results for the second quarter ending June ... many fronts across the organization.  We are excited to ... dystrophy clinical trial ever conducted with topline results expected ... Chief Executive Officer, PTC Therapeutics, Inc. "Translarna is now ...
(Date:7/30/2015)... WOODCLIFF LAKE, N.J. , July 30, 2015 /PRNewswire/ ... submitted simultaneously in the United States ... (to the FDA, EMA and MHLW, respectively) for eribulin, ... sarcoma (STS) who have received prior chemotherapy for advanced ... are based on data from a pivotal global Phase ...
(Date:7/30/2015)... FAIRFIELD, N.J. , July 30, 2015 /PRNewswire/ ... Ferrer, completed the second Phase III clinical study ... development for impetigo.  Medimetriks owns the exclusive U.S. ... The global trial, conducted at 44 centers with ... and pediatric patients aged 2 months and older ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... Voreloxin Demonstrates Promising Clinical Activity in Patients with ... Difficult-to-Treat ... Sunesis,Pharmaceuticals, Inc. (Nasdaq: SNSS ) presented data from three ... the Chemotherapy Foundation Symposium held in New York on November ...
... 5 Medarex, Inc.,(Nasdaq: MEDX ) today ... of,an undisclosed amount from its licensing partner, Centocor ... trial of CNTO 95, a fully human antibody,targeting ... The CNTO 95 human antibody was generated using ...
Cached Medicine Technology:Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 2Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 3Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 4Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium 5Medarex Receives Milestone Payment for Investigational Antibody Targeting Integrin Receptors 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: